Instil Bio, Inc. (NasdaqCM: TIL)
Health Care · Biotechnology · US
$7.81
+3.03% today · -69.6% 1Y
Instil Bio, Inc. (NasdaqCM: TIL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $52.97M and employs 17 people.
Over the last twelve months the share price has lost 69.6%, trading between 5.67 and 33.83.
Tweenvest scores Instil Bio, Inc. across four factors: quality 23/100. Its strongest factor is quality.
TIL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.97M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.47
- Dividend yield
- —
- Beta (5Y)
- 1.91
- 52-week high
- $33.83
- 52-week low
- $5.67
- Avg volume (3M)
- —
- Shares outstanding
- 6.78M
- Employees
- 17
- Next earnings
- —
About Instil Bio, Inc.
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
- ISIN
- US45783C2008
- Founded
- 2018
- Listed since
- Mar 19, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | 0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.53 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.11 | +1.60% |
Figures last refreshed Aug 18, 2026.